NICE Issues Two Major 2025 Approvals: Vutrisiran for ATTR-CM and Aucatzyl CAR-T for R/R B-ALL
NICE has issued two major decisions: recommending vutrisiran for adult ATTR-CM and approving Aucatzyl CAR-T for relapsed or refractory B-ALL in adults.
NICE Recommendations
NICE Recommends Nanox.AI’s Spine-Fracture Detection Tools for Early Value Assessment Across NHS Hospitals
NICE has recommended Nanox.AI’s HealthOST and HealthVCF for Early Value Assessment, enabling NHS hospitals to deploy the AI tools for three years while gathering evidence on their value in detecting vertebral fragility fractures. The decision marks an important step in advancing AI-driven early detection of osteoporosis.
NICE Issues New Updates on AI Cancer Detection, Sepsis Care, and Breast Cancer Drug Appraisal
NICE has published three updates spanning diagnostics, acute care, and oncology: conditional support for AI tools that detect bowel cancer polyps, new sepsis guidelines emphasizing tailored treatment, and the termination of a trastuzumab deruxtecan appraisal after no company evidence submission.
NICE Expands Cancer and Dermatology Options With Three Major Recommendations Across DLBCL, Myeloma, and Chronic Hand Eczema
NICE has issued three major recommendations expanding access to Columvi-GemOx for DLBCL, talquetamab for relapsed myeloma, and delgocitinib for chronic hand eczema.
NICE Secures Breakthrough HTA Decision for Prostate Cancer
NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.
Synopulse Weekly: Top Deals, FDA Moves & Pricing Insights
Top biopharma deals, FDA approvals, and market access news from the past week.
NICE Endorses Linzagolix for NHS Endometriosis Care
The National Institute for Health and Care Excellence (NICE) has approved linzagolix combined with hormonal add-back therapy for endometriosis treatment within the NHS, expanding therapeutic options for an estimated 1.5 million women in the UK affected by this chronic condition. Clinical trials have substantiated that linzagolix effectively reduces both dysmenorrhea and non-menstrual pelvic pain in … Read more
LifeScience Weekly Digest: Key Industry Updates (13th – 17th January)
JP Morgan Week featured notable developments in drugs, devices, diagnostics, and digital health. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies, bolstering its neuroscience portfolio with CAPLYTA® and a strong mental health pipeline. Eli Lilly invested $2.5 billion in Scorpion Therapeutics’ PI3Kα inhibitor for hormone-positive breast cancer, while Bausch + Lomb expanded ophthalmology with … Read more